BioNTech SE (ETR:22UA)
Market Cap | 21.42B |
Revenue (ttm) | 2.75B |
Net Income (ttm) | -766.00M |
Shares Out | n/a |
EPS (ttm) | -3.19 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 143 |
Average Volume | 1,712 |
Open | 91.85 |
Previous Close | 94.05 |
Day's Range | 89.45 - 92.65 |
52-Week Range | 69.70 - 124.60 |
Beta | 1.08 |
RSI | 46.72 |
Earnings Date | May 5, 2025 |
About BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in ph... [Read more]
Financial Performance
Financial StatementsNews
BioNTech SE 2025 Q1 - Results - Earnings Call Presentation
BioNTech GAAP EPS of -€1.73, revenue of €182.8M; reaffirms FY25 outlook
BioNTech press release (BNTX): Q1 GAAP EPS of -€1.73. Revenue of €182.8M (-2.6% Y/Y). Cash and cash equivalents plus security investments as of March 31, 2025, reached €15,854.4 million,

BioNTech Announces First Quarter 2025 Financial Results and Corporate Update
Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A 1 , and mRNA...

BioNTech says Novartis executive Zapata-Gomez to become CFO
German COVID-19 vaccine maker BioNTech said on Monday that Ramon Zapata-Gomez will become its new finance chief from July 1.

BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer
Mainz, Germany, May 5, 2025 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Ramón Zapata-Gomez to the Management Boa...
Earnings Scheduled For May 5, 2025
Companies Reporting Before The Bell • Recursion Pharmaceuticals (NASDAQ: RXRX) is likely to report quarterly loss at $0.52 per share on revenue of $18.08 million. • Freshpet (NASDAQ: FRPT) is estima...
BioNTech Q1 2025 Earnings Preview

Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today

Prediction: 1 Biotech Stock That Could Surpass Pfizer by 2030
Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a $128 billion market cap. Renowned for its blockbuster drugs like Lipitor an...

BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025
MAINZ, Germany, April 24, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer immunother...
BioNTech Surges On Summit's Coattails. But Can They Take On Merck?
BioNTech stock rocketed Wednesday after rival Summit Therapeutics unveiled promising results for a novel approach to lung cancer treatment.

BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025
MAINZ, Germany, April 22, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2025 on Monday, May 5, 2025. Additi...

BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025
MAINZ, Germany, April 22, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2025 on Monday, May 5, 2025. Additi...
Vaccine stocks fall following FDA resignation
Dr. Kavita Patel joins 'Fast Money' to talk the impact of FDA and HHS changes on vaccines, public health policy, and more.

Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views
Stocks of major vaccine makers dropped on Monday after the Food and Drug Administration's (FDA) top vaccine official Dr. Peter Marks resigned, citing conflicts with Health and Human Services (HHS) Sec...

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul
Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump admin...

Vaccine stocks fall after key FDA official resigns in protest of RFK Jr.
Shares of vaccine makers Moderna and Novavax, along with a range of other biotech companies, fell after the resignation of key FDA official Peter Marks. Marks stepped down in protest of Health and Hum...

Biotech stocks tumble on reports FDA's top vaccine regulator to leave
Shares of U.S. biotech companies fell as much as 10% premarket on Monday following reports that a top vaccine official at the U.S. Food and Drug Administration had resigned, fanning worries over slowe...

CureVac Shares Rise on Patent Confirmation Amid BioNTech Lawsuit
Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech.

European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps
CureVac N.V. (NASDAQ: CVAC) on Thursday said the European Patent Office (EPO) confirmed the validity of CureVac’s European patent EP 3 708 668 B1 subject to amendments to specify the scope of protect...
CureVac up 13% as court upholds validity of patent in BioNTech spat

CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amended formA hearing on infringement of EP 3...

EQS-News: CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
Issuer: CureVac / Key word(s): Patent CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE 27.03.2025 / 21:05 CET/CEST The issuer is solely respons...

Looking At BioNTech's Recent Unusual Options Activity
Deep-pocketed investors have adopted a bearish approach towards BioNTech (NASDAQ: BNTX), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveile...

Refractory Metastatic Melanoma Pipeline Report 2025, with Focus on BioNTech SE, Y-mAbs and Therapeutics Seagen
Dublin, March 20, 2025 (GLOBE NEWSWIRE) -- The "Refractory Metastatic Melanoma - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. The report provides compre...